Efficacy and safety of fludarabine/cyclophosphamide (FC) as front-line treatment of CLL. Final results of a phase II clinical trial in a single center.

被引：0
|
作者：
Marin-Niebla, A [1 ]
Rios-Herranz, E [1 ]
Rodriguez, JM [1 ]
Nunez, R [1 ]
Herrera, A [1 ]
Parody, R [1 ]
Espigado, I [1 ]
机构：
[1] Hosp Virgen Rocio, Seville, Spain
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.4826.4826
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4826
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of Fludarabine/Cyclophosphamide (FC) as front-line treatment of CLL.: Preliminary results of a phase II clinical trial.
    Marin-Niebla, A
    Herranz, ER
    Fernandez, JMR
    Nuñez, R
    Allegue, MJ
    Carreira, JP
    Espigado, I
    BLOOD, 2003, 102 (11) : 354B - 354B
  • [2] Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study
    Herishanu, Yair
    Levi, Shai
    Goldschmidt, Neta
    Morabito, Fortunato
    Bairey, Osnat
    Del Poeta, Giovanni
    Baran, Tomer Ziv
    Fineman, Riva
    Mauro, Francesca Romana
    Gutwein, Odit
    Reda, Gianluigi
    Ruchlemer, Rosa
    Sportoletti, Paolo
    Laurenti, Luca
    Shvidel, Lev
    Coscia, Marta
    Tadmor, Tamar
    Varettoni, Marzia
    Aviv, Ariel
    Murru, Roberta
    Breaster, Andrei
    Bronstein, Yotam
    Chiarenza, Annalisa
    Visentin, Andrea
    Pietrasanta, Daniela
    Loseto, Giacomo
    Zucchetto, Antonella
    Bomben, Riccardo
    Olivieri, Jacopo
    Neri, Antonino
    Rossi, Davide
    Gaidano, Gianluca
    Trentin, Livio
    Foa, Robin
    Cuneo, Antonio
    Gattei, Valter
    Gentile, Massimo
    BLOOD, 2021, 138
  • [3] FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) VERSUS CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (CVP) AS FIRST LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). SINGLE CENTER EXPERIENCE
    Ionita, H.
    Chreveresan, L.
    Mihaescu, R.
    Ionita, I.
    Isac, A.
    Cheveresan, M.
    Oros, D.
    Iordache, M.
    Musta, I.
    Basa, N.
    Delamarian, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 468 - 468
  • [4] Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience
    Herishanu, Yair
    Goldschmidt, Neta
    Bairey, Osnat
    Ruchlemer, Rosa
    Fineman, Riva
    Rahimi-Levene, Naomi
    Shvidel, Lev
    Tadmor, Tamar
    Ariel, Aviv
    Braester, Andrea
    Shapiro, Mika
    Joffe, Erel
    Polliack, Aaron
    HAEMATOLOGICA, 2015, 100 (05) : 662 - 669
  • [5] Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study
    Mauro, Francesca Romana
    Zaja, Francesco
    Molica, Stefano
    Coscia, Marta
    Liberati, Anna Marina
    Piciocchri, Alfonso
    Ilariucci, Fiorella
    Russo, Fiiomena
    Re, Francesca
    Tedeschi, Alessandra
    Baraldi, Anna
    Carella, Angelo Michele
    Gozzetti, Alessandro
    Del Poeta, Giovanni
    Cortelezzi, Agostino
    Battistini, Roberta
    Iannella, Emilia
    Ferretti, Antonietta
    Del Giudice, Ilaria
    Della Starza, Irene
    Raponi, Sara
    De Propris, Maria Stefania
    Ilari, Caterina
    Cafforio, Luciana
    Nanni, Mauro
    Fazi, Paola
    Vignetti, Marco
    Neri, Antonino
    Specchia, Giorgina
    Cuneo, Antonio
    Guarini, Anna
    Foa, Robin
    BLOOD, 2015, 126 (23)
  • [6] Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)
    Ciccone, Maria
    Vitale, Candida
    Hinojosa, Christina
    Keating, Michael J.
    Pemmaraju, Naveen
    O'Brien, Susan
    Burger, Jan A.
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Strati, Paolo
    Wierda, William G.
    Ferrajoli, Alessandra
    BLOOD, 2014, 124 (21)
  • [7] Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial.
    Chanan-Khan, AA
    Fallon, A
    Miller, K
    Bernstein, ZP
    Hernandez, F
    Alam, A
    McCarthy, P
    Mohr, A
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 675A - 675A
  • [8] The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
    Anter, Abeer Hussien
    Abdel-Latif, Rasha Mohamed
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [9] The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
    Abeer Hussien Anter
    Rasha Mohamed Abdel-Latif
    Medical Oncology, 2013, 30
  • [10] A multicenter, open label, uncontrolled, phase II clinical trial evaluating the safety and efficacy of venetoclax in combination with atezolizumab and obinutuzumab in richter transformation of CLL.
    Montillo, Marco
    Rossi, Davide
    Zucca, Emanuele
    Frustaci, Anna Maria
    Pileri, Stefano
    Cavalli, Franco
    Tedeschi, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345